Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALISCHER-SAH: Ticagrelor vs placebo to prevent cerebral ischemia in low-grade aneurysmal subarachnoid hemorrhage
2023-509795-42-00Phase 3Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in subarachnoid hemorrhage (SAH) and brain ischemia comparing Ticagrelor (Brilique) with Placebo (2 arms). Primary endpoint: Symptomatic and asymptomatic peri-procedural thromboembolic events (0–24 hours). Planned start Jun 2026; status: authorised.
02
Drugs
ticagrelor
03
Conditions
subarachnoid hemorrhage (SAH)brain ischemia
Beyond the preview
Go deeper on 2023-509795-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509795-42-00.